Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Duck reovirus (DRV) strain TH11 is a highly pathogenic avian orthoreovirus that causes significant economic losses in the poultry industry, particularly through spotted liver disease in Muscovy ducks (Zhang et al., 2019). The virion antigens, which include structural proteins like sigma C (σC), sigma B (σB), and mu B (μB), are the primary targets for neutralizing antibodies (Yun et al., 2014). The σC protein is especially important as it functions as the viral attachment protein, facilitating entry into host cells; therefore, it is a major focus for vaccine development (Wang et al., 2020). These antigens are considered indirect immune targets because therapeutic interventions, such as inactivated or subunit vaccines, are designed to elicit a host antibody response that subsequently neutralizes the virus (Chen et al., 2018). Additionally, hyperimmune yolk antibodies (IgY) are used as a passive immunotherapy to provide immediate protection by binding to these virion antigens and preventing infection in young ducklings (Wu et al., 2021). Understanding the antigenic structure of the TH11 strain is crucial for overcoming challenges related to antigenic variation and ensuring the efficacy of immunization programs. The interaction between host antibodies and these antigens is the cornerstone of both natural immunity and clinical management of the disease.
Neutralization of viral infectivity by blocking attachment to host receptors and promoting viral clearance via antibody-mediated mechanisms.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Duck reovirus TH11 virion antigen (DRV TH11 antigen).